(XLV) Health Care Sector Fund - Overview
Etf: Pharmaceuticals, Equipment, Providers, Biotechnology, Life Sciences
Dividends
| Dividend Yield | 1.74% |
| Yield on Cost 5y | 2.32% |
| Yield CAGR 5y | 7.22% |
| Payout Consistency | 96.3% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 14.7% |
| Relative Tail Risk | -0.76% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | -1.77 |
| Character TTM | |
|---|---|
| Beta | 0.500 |
| Beta Downside | 0.500 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.11% |
| CAGR/Max DD | 0.46 |
Description: XLV Health Care Sector Fund December 17, 2025
The Health Care Select Sector SPDR® Fund (XLV) seeks to replicate the S&P 500 Health Care Index by investing at least 95 % of its assets in the index’s constituents. Its exposure spans pharmaceuticals, health-care equipment & supplies, providers & services, biotechnology, life-sciences tools & services, and health-care technology, making it a non-diversified ETF focused exclusively on the U.S. health-care sector.
Key metrics (as of Q3 2024) show an expense ratio of 0.12 % and a 12-month total return of roughly 8 %, driven largely by strong earnings from top holdings such as UnitedHealth Group, Johnson & Johnson, and Pfizer. The sector’s growth is underpinned by macro drivers like an aging population, rising Medicare/Medicaid spending, and sustained biotech R&D pipelines, which together contribute to a long-term revenue expansion rate estimated at 5-6 % annually for the broader health-care industry.
For deeper quantitative analysis, you may find ValueRay’s platform useful for drilling into XLV’s holdings and risk metrics.
What is the price of XLV shares?
Over the past week, the price has changed by +1.30%, over one month by -0.26%, over three months by +7.54% and over the past year by +9.70%.
Is XLV a buy, sell or hold?
What are the forecasts/targets for the XLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 170.3 | 8% |
XLV Fundamental Data Overview February 07, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 41.85b USD (41.85b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 41.85b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 41.85b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.76% (E(41.85b)/V(41.85b) * Re(7.76%) + (debt-free company))
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)